Stay updated on Durvalumab & Tremelimumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Durvalumab & Tremelimumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Durvalumab & Tremelimumab in NSCLC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    7 days ago
    Change Detected
    Summary
    The record for the completed ARCTIC lung cancer trial is now available, with study details, participant criteria, treatment arms, outcome measures, and results-related resources. It also includes links to study documents and information about requesting access to individual participant data.
    Difference
    100%
    Check dated 2026-11-09T12:35:11.000Z thumbnail image
  3. Check
    14 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-11-02T11:57:43.000Z thumbnail image
  4. Check
    21 days ago
    Change Detected
    Summary
    A site-wide banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology and links to related updates and FAQs.
    Difference
    1%
    Check dated 2026-10-26T11:22:00.000Z thumbnail image
  5. Check
    28 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.1 to v3.7.2 while the study page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-19T12:14:57.000Z thumbnail image
  6. Check
    35 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-12T14:48:20.000Z thumbnail image
  7. Check
    56 days ago
    Change Detected
    Summary
    A new Revision: v3.7.0 is shown, and several key study documents and contact/resources have been redacted or removed from the Study Documents section, reducing access to the SAP, CSP, and related materials.
    Difference
    17%
    Check dated 2026-09-21T22:25:52.000Z thumbnail image

Stay in the know with updates to Durvalumab & Tremelimumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Durvalumab & Tremelimumab in NSCLC Clinical Trial page.